In Depth 30 Jan 2026 Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma? Discover J&J’s pipeline strategy for 2026 as it it projects that its sales for the year will be between $100 billion and $101 billion. January 30, 2026 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 27 Jan 2026 How the University of North Carolina at Chapel Hill is enhancing RNAi potency with its new technology Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi potency. January 27, 2026 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 26 Jan 2026 A clearer path to relief: sinusitis treatments on the way Emerging sinusitis treatments include monoclonal antibodies to tackle the unmet medical needs of patients. January 26, 2026 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 23 Jan 2026 What does 2026 hold for the biotech industry? Delve into what 2026 has to offer in the biotech industry. The market is showing signs it’s picking up and the patent cliff is driving deals. January 23, 2026 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 21 Jan 2026 Could CRISPR really cure these diseases? Here are some of the diseases that scientists aim to tackle using CRISPR technology, testing its possibilities and limits as a medical tool. January 21, 2026 - 16 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 20 Jan 2026 Hepatitis B: Are we edging closer to a cure? Find out whether we are closing in on a cure for hepatitis B – a virus affecting the liver that can cause acute and chronic disease. January 20, 2026 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 14 Jan 2026 The AbbVie strategy, a company at an inflection point Look into AbbVie’s strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent cliff. January 14, 2026 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 9 Jan 2026 The biggest biotech funding rounds in December 2025 The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in December 2025. January 9, 2026 - 4 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 7 Jan 2026 Top biotech deals in December 2025 As we head into the 2026, let’s take a look at biotech licensing deals and M&As that were inked in December 2025. January 7, 2026 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 16 Dec 2025 Biotech in 2025: A retrospective Take a look back into biotech in 2025 as the year is closing – from GLP-1s to radiopharmaceuticals and neuroplastogens. December 16, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 10 Dec 2025 Promising cure for COPD: Is a breakthrough treatment within reach? Find out whether a promising cure for COPD is within reach, after recent advancements in treatments and research around the disease. December 10, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Dec 2025 When AI isn’t enough: How physics is shaping the next wave of drug discovery Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech – the AI and physics combo. December 9, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email